Initial clinical data expected in 1H 2021
Cambridge, MA and Gosselies, Belgium – February 27, 2020 – iTeos Therapeutics Inc., a privately-held clinical-stage biotechnology company developing
Potentially pivotal trial for industry’s most-advanced cell-based therapy in severe liver diseases expected to generate results in H2 2023
Mont-Saint-Guibert, Belgium, and Tokyo, Japan, January 8th
Belgium – 19 December 2019 – Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment
Total amount raised in the Series D reaches €47.2 Million.
Mont-Saint-Guibert, Belgium, and Tokyo, Japan, December 16, 2019 – Promethera® Biosciences SA, a global innovator in cell-based medicines
Study will evaluate the safety and efficacy of the combination of iTeos’ EOS100850 and Merck’s KEYTRUDA® (pembrolizumab)
Gosselies, Belgium and Cambridge, MA – Dec. 12, 2019 – iTeos Therapeutics
- Bringing Innovative Liver-Focused Cell therapies to Japanese Markets -
Promethera® Biosciences SA (“Promethera®”) and MEDIPAL HOLDINGS CORPORATION (“MEDIPAL”) today announced that they have
Belgium – 5 November 2019 – Syndesi Therapeutics SA, a biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment, today announced
Study highlights potential benefit in rare pediatric orthopedic disorder
Mont-Saint-Guibert, Belgium, October 2, 2019 : Novadip Biosciences (“Novadip” or “the company”), a clinical-stage
GO plc in Malta has launched a converged fixed and mobile solution using Tessares’s Multipath TCP technology. Available to all GO plc customers, this solution combines the operator's fixed network
After a first order of its flagship product - the best dry ginseng in the world - in May 2018, Pierre-Antoine Mariage and Paul-Evence Coppée are expanding internationally thanks to important contracts
VIVES, a long-standing investor in iTeos Therapeutics, participated in the Series B €64 million fundraise. The lead and new investor, the American fund MPM Capital, will allow the UCLouvain spin-off
A-Mansia Biotech S.A. is active in the microbiome field based on pioneering research on Akkermansia muciniphila (A. muciniphila) from two well-known scientists, Prof. P. Cani (Université catholique de
